...
首页> 外文期刊>Clinical and experimental medicine >Gene delivery of soluble vascular endothelial growth factor receptor-1 (sFlt-1) inhibits intra-plaque angiogenesis and suppresses development of atherosclerotic plaque.
【24h】

Gene delivery of soluble vascular endothelial growth factor receptor-1 (sFlt-1) inhibits intra-plaque angiogenesis and suppresses development of atherosclerotic plaque.

机译:可溶性血管内皮生长因子受体1(sFlt-1)的基因传递抑制斑块内血管生成,并抑制动脉粥样硬化斑块的发展。

获取原文
获取原文并翻译 | 示例
           

摘要

Intra-plaque angiogenesis plays an important role in the development of atherosclerotic plaque. Vascular endothelial growth factor (VEGF) is a major initiating factor in this pathologic progress. One selective and specific inhibitor of VEGF is soluble VEGF receptor-1 (sFlt-1). The anti-angiogenic utilization of sFlt-1 in treatment of atherosclerotic plaque has not been fully confirmed yet. Our study was designed to construct eukaryotic expression recombinant pEGFP-N1-sFlt-1, evaluate sFlt-1 recombinant's effects on endothelial cells proliferation and tube formation in vitro, and investigate effects of local high-expressed sFlt-1 on atherosclerotic plaque in vivo. Rabbit models of atherosclerotic plaque were established by high-lipid diet combined with injury induced by balloon catheter on iliac artery intima. Animals were divided into four groups randomly: control group (C), atherosclerotic plaque group (AP), atherosclerotic plaque with blank vector pEGFP-N1 transfection group (APV), and atherosclerotic plaque with pEGFP-N1-sFlt-1 transfection group (APsFlt-1). The local expression of sFlt-1 protein in target artery was detected by western blotting. The plaque area (PA), plaque circumference (PC), and maximum plaque thickness (MPT) were measured via HE staining. Degree of intra-plaque angiogenesis was evaluated by CD34+ cells immunohistochemistry. As results, we observed that pEGFP-N1-sFlt-1 transfection suppressed the HUVECs proliferation and ability of tube formation, against the effect of VEGF. We obtained higher local expression of sFlt-1 protein in Group APsFlt-1 than that in other groups (P < 0.05). PA, PC, and MPT of plaque in group APsFlt-1 were significantly decreased when compared with other groups (P < 0.05). Amount of annulations surrounded by CD34-positive cells was significantly decreased in pEGFP-N1-sFlt-1 transfection group, which represented decreased level of intra-plaque neovessels formation. The present study confirmed that local gene delivery of sFlt-1 can suppress plaque formation, as one of possible mechanisms, via inhibitive effect on intra atherosclerotic plaque angiogenesis, which hints at the clinical utility of sFlt-1 in atherosclerosis therapy.
机译:斑块内血管生成在动脉粥样硬化斑块的发展中起重要作用。血管内皮生长因子(VEGF)是这一病理进展的主要启动因子。 VEGF的一种选择性和特异性抑制剂是可溶性​​VEGF受体1(sFlt-1)。 sFlt-1在治疗动脉粥样硬化斑块中的抗血管生成作用尚未得到完全证实。我们的研究旨在构建真核表达重组pEGFP-N1-sFlt-1,评估sFlt-1重组体对体外内皮细胞增殖和管形成的影响,并研究局部高表达的sFlt-1对体内动脉粥样硬化斑块的影响。高脂饮食结合气囊导管对induced动脉内膜造成的损伤,建立了兔动脉粥样硬化斑块模型。将动物随机分为四组:对照组(C),动脉粥样硬化斑块组(AP),带有空白载体pEGFP-N1转染组(APV)的动脉粥样硬化斑块和带有pEGFP-N1-sFlt-1转染组(APsFlt的动脉粥样硬化斑块) -1)。通过western印迹检测sFlt-1蛋白在靶动脉中的局部表达。通过HE染色测量斑面积(PA),斑周长(PC)和最大斑厚度(MPT)。通过CD34 +细胞免疫组织化学评估斑块内血管生成的程度。结果,我们观察到pEGFP-N1-sFlt-1转染抑制了HUVEC的增殖和管形成的能力,抵抗了VEGF的作用。我们在APsFlt-1组中获得了比其他组更高的sFlt-1蛋白局部表达(P <0.05)。与其他组相比,APsFlt-1组的斑块的PA,PC和MPT显着降低(P <0.05)。在pEGFP-N1-sFlt-1转染组中,被CD34阳性细胞包围的环空量显着减少,这表明斑块内新血管形成水平降低。本研究证实,sFlt-1的局部基因递送可以通过抑制动脉粥样硬化斑块内血管生成的方式抑制斑块形成,这是一种可能的机制,这暗示了sFlt-1在动脉粥样硬化治疗中的临床应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号